3 Cannabis Developments Investors Need to Know About Today

Tilray Inc. (NASDAQ:TLRY) and HEXO Corp. (TSX:HEXO)(NYSE:HEXO) are two key stocks to keep an eye on as the cannabis space ramps up for winter.

| More on:
edit Jars of marijuana

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The cannabis investment space is never short of headlines. However, three developments could have lasting implications for your favourite weed stocks over the winter. Here are three of the top legal marijuana breakthroughs to keep an eye on over the holiday season.

China ramps up its CBD business

China could be the latest growth market for CBD. While this should be no surprise for anyone with a working knowledge of the history of the herb – China has been growing hemp for millennia – the fact that the Asian powerhouse wants to increase its standing in international markets for the compound may come as something of a surprise to casual cannabis investors.

However, China is already a key producer of CBD for the global market, and accounted for approximately 11% of the worldwide market last year. Though the country will not be involved in THC production, as the high-inducing drug is strictly illegal in the country, China will be looking to compete with Europe and the U.S. on the global CBD market.

Tilray posts its Q3 report

International markets are likely to be key for North American cannabis companies. Tilray (NASDAQ:TLRY) pointed out on the Q3 conference call this week that the company’s EU Campus in Portugal exported its first shipment of medical cannabis to Germany through a $3 million deal to supply patients. Indeed, the European segment of North American cannabis companies is likely to be an important driver of growth.

However, Tilray’s third-quarter results are more than a little mixed. While revenues were up by a massive 411% and kilogram equivalents sold were up 573%, the average net price per gram was down by 48%.

Investors have thrashed Tilray this past few days, sending it tumbling 7%, while a non-GAAP loss of 163% makes for uneasy reading.

Cannabis 2.0 products will finally test the market

The fight against the black and grey markets is ramping up. HEXO (TSX:HEXO)(NYSE:HEXO) has brought out a new brand, Original Stash, with the explicit function of tackling underground sales by hitting where it hurts: the bottom line.

What’s notable about the move is that it marks a shift in HEXO’s business modus operandi from a skimming model to a penetration model, wherein competitors are undercut in terms of price.

On another battle front, HEXO’s range of cannabis drinks will hit the shelves over the holiday period in the first test of the legal pot-infused beverages market in Canada. The cannabis drinks industry has a rough market size of around $500 million a year.

After trading flat for a while, HEXO is down 6.3% in the last five days. However, while a “normal” stock down by a few points would be an unwelcome flash of red in a portfolio, to see HEXO trading in this range is still an improvement on its performance a few weeks ago when it led the cannabis sector off a cliff. Overall, HEXO has lost almost 60% in the last three months.

The bottom line

HEXO has got its act together in terms of branding. Its Original Stash brand, launched only recently, signals an about-face in its business model, tackling the black and grey markets by price-matching illegal marijuana prices. Meanwhile, investors are about to find out just what the market really is for Cannabis 2.0 products.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Victoria Hetherington has no position in any of the stocks mentioned. The Motley Fool recommends HEXO. and HEXO.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »